Despite the availability of advanced therapeutic options, the Uterine Fibroid Market is characterized by persistent global and domestic disparities in care.

Global Disparities: In low- and middle-income countries, lack of access to diagnostic imaging (MRI) and expensive, specialized procedures (MRgFUS, robotic myomectomy) often forces reliance on less advanced surgical options, leading to disproportionately higher rates of hysterectomy.

Racial Disparities (High-Income Nations): Racial and ethnic minorities, particularly Black women, experience a higher incidence, earlier onset, and more severe symptoms. Studies show that these populations are significantly less likely to be offered or utilize minimally invasive options like Uterine Artery Embolization (UAE) compared to surgical options, and are more likely to undergo hysterectomy at younger ages. Addressing these equity issues requires improved clinical guidelines, public education, and systemic changes to eliminate bias in treatment recommendation, which is a major focus for future health policy in the Uterine Fibroid Market, as highlighted in health equity research, such as the Uterine Fibroid Market Global Outlook.